PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31685558-0	2019	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.	rucaparib	64-73	BRCA1 DNA repair associated	Homo sapiens	136-140	
31685558-1	2019	OBJECTIVE: To report results from an integrated efficacy and safety analysis supporting the European Commission"s approval of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy treatment for relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.	rucaparib	168-177	BRCA1 DNA repair associated	Homo sapiens	237-241	
31685558-9	2019	CONCLUSIONS: In patients with platinum-sensitive, BRCA-mutated ovarian cancer, rucaparib demonstrated antitumor activity and is the first and currently the only poly(ADP-ribose) polymerase inhibitor approved by the European Commission as treatment for this population.	rucaparib	79-88	BRCA1 DNA repair associated	Homo sapiens	50-54